Eczema
(atopic dermatitis)
study now enrolling!

see if you
qualify

PRESS RELEASES

Year
May 25 | 2023
RAPT Therapeutics to Present Biomarker Data Corroborating Demonstrated Clinical Activity and Mechanism of Action of FLX475 in Advanced Cancers
May 11 | 2023
RAPT Therapeutics Reports First Quarter 2023 Financial Results
May 03 | 2023
RAPT Therapeutics Announces the Appointment of Michael Listgarten as General Counsel
May 03 | 2023
RAPT Therapeutics Announces the Appointment of Michael Listgarten as General Counsel
April 26 | 2023
RAPT Therapeutics Announces FLX475 Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
March 29 | 2023
RAPT Therapeutics Announces Initiation of Phase 2a Trial of RPT193 in Patients with Moderate-to-Severe Asthma
March 14 | 2023
RAPT Therapeutics Reports Fourth Quarter And Year End Financial Results
February 07 | 2023
RAPT Therapeutics to Participate in the SVB Securities Global Biopharma Conference
January 03 | 2023
RAPT Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
December 08 | 2022
RAPT Therapeutics Presents Update from its Phase 1/2 Clinical Trial for FLX475 as Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Cancer